2TK Stock Chart & Stats
€3.20
€0.04(1.27%)
At close: 4:00 PM EDT
€3.20
€0.04(1.27%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€233.67M
Enterprise Value€398.44
Total Cash (Recent Filing)€88.76M
Total Debt (Recent Filing)€467.00K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 18, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume15
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.13Price Target Upside154.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces solvency pressure and interest obligations, giving Eledon greater flexibility to direct available capital toward clinical development and potentially withstand funding cycles better than a highly leveraged biotech.
Phase 3 Regulatory ProgressAdvancing the regulatory framework toward Phase 3 is a durable development milestone that can improve the program’s probability of reaching pivotal testing and create a clearer path toward potential commercialization.
Broad Tegoprubart Clinical PotentialEvidence across kidney and islet cell transplantation supports tegoprubart’s potential utility in multiple transplant settings, strengthening pipeline optionality and reducing dependence on a single narrowly defined indication.
Bears Say
No Commercial RevenueThe absence of revenue confirms that Eledon remains dependent on clinical progress and external financing rather than operating income. Deep losses also leave limited evidence that the business model can reach breakeven.
Persistent Cash BurnLarge and worsening cash consumption raises the likelihood of additional capital requirements before commercialization. Continued funding needs can constrain development choices and increase exposure to financing and dilution risk.
Shrinking Equity Base And Dilution RiskFalling equity reflects cumulative losses, while the expanded share authorization provides capacity for future fundraising. Together, these factors indicate ongoing capital dependence and a meaningful risk of shareholder dilution.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is €233.67M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 82 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -€0.233 earnings per share for the quarter, missing the consensus estimate of -€0.136 by -€0.097.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 81,261,154 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -€0.233 in its last earnings report, missing expectations of -€0.136. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.13 (154.14% Upside)
€8.13 (154.14% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.98%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€8.13
▲(154.14% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
ProQR
―
Bicycle Therapeutics
―
SAB Biotherapeutics
―